Immunotech Biopharm's (HKG:6978) loss attributable to owners in 2024 narrowed year on year to 186.9 million yuan or 0.36 per share from 334.8 million yuan or 0.65 yuan per share, according to a Hong Kong Stock Exchange disclosure on Monday.
The biopharmaceutical company's other income surged 220% to 33.8 million yuan from 10.5 million yuan in the previous year.
No dividend was recommended for the period.